Interaction of SQ 20009 and GABA-like drugs as modulators of benzodiazepine receptor binding.
SQ 20009, a new anxiolytic drug structurally unrelated to GABA or benzodiazepines, has two modulatory effects on the binding of 3H-flunitrazepam to membranes from rat cerebellum. Thus, SQ 20009 has a direct and chloride ion dependent stimulatory effect on benzodiazepine receptor binding which in turn appears to be modulated by the associated GABA receptor. In addition SQ 20009 has indirect effects on benzodiazepine receptor binding since it enhances the potency of GABA and muscimol to stimulate 3H-flunitrazepam binding.
D000818:Animals; D001569:Benzodiazepines / Q000378:metabolism*; D002531:Cerebellum / Q000378:metabolism*; D004347:Drug Interactions; D004974:Etazolate / Q000494:pharmacology*; D005445:Flunitrazepam / Q000378:metabolism; D066298:In Vitro Techniques; D008566:Membranes / Q000378:metabolism; D009118:Muscimol / Q000494:pharmacology; D009539:Nicotinic Acids / Q000494:pharmacology*; D051381:Rats; D011955:Receptors, Drug / Q000187:drug effects* / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology*
D009539:Nicotinic Acids; D011955:Receptors, Drug; D001569:Benzodiazepines; D009118:Muscimol; D005680:gamma-Aminobutyric Acid; D005445:Flunitrazepam; D004974:Etazolate